Contemporary therapeutic strategies for diabetes management encompass several pharmacological approaches: enhancement of insulin secretion using sulfonylureas and glucagon-like peptide-1 (GLP-1) receptor agonists, regulation of hepatic gluconeogenesis mediated by biguanides, and the use of sodium–glucose cotransporter-2 (SGLT-2) inhibitors, which function primarily to reduce the glycemic levels and thereby prevent or attenuate the late-stage complications associated with this metabolic disorder [5,6,7]. Here, INS is linked to diabetes mellitus.